IMUX Archives - BioTuesdays

Executive Moves

Immunic appoints Michael W. Bonney as BoD chair

Immunic (NASDAQ: IMUX) has announced the appointment of biopharmaceutical executive Michael W. Bonney as chair of its board of directors (BoD), effective May 16, 2026. Simona Skerjanec, MPharm, MBA, will transition from...

May 19, 2026

Markets

Stifel starts Immunic at buy; PT $2.50

Stifel initiated coverage of Immunic (NASDAQ: IMUX) with a “buy” rating and price target of $2.50. The stock closed at $1.11 on April 15. Immunic is a biotechnology company developing vidofludimus calcium (VidoCa) for...

April 16, 2026

Developments

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...

June 24, 2025

Developments

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Immunic (NASDAQ:IMUX) announced positive Phase 2 CALLIPER data demonstrating its nuclear receptor related 1 (Nurr1) activator—vidofludimus calcium (IMU-838)—reduced the risk of progressive multiple sclerosis (PMS)...

April 30, 2025

Developments

Immunic posts positive Phase 1b results in celiac disease

Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...

May 4, 2023

Markets

SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...

October 2, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Markets

Roth starts Immunic at buy; PT $44

Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...

March 25, 2020

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

Markets

Ladenburg starts Immunic at buy; PT $50

Ladenburg Thalmann initiated coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $50 price target. The stock closed at $14.30 on April 22.

April 23, 2019

Tag - IMUX

Immunic appoints Michael W. Bonney as BoD chair

Stifel starts Immunic at buy; PT $2.50

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Immunic posts positive Phase 1b results in celiac disease

SVB Leerink starts Immunic at OP, PT $45

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Roth starts Immunic at buy; PT $44

Immunic completes enrollment for Phase 2 MS trial

Ladenburg starts Immunic at buy; PT $50

Subscribe